Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages

  Federica, Meloni ^a   Nadia, Solari ^a   Monica, Morosini ^a   Alessandro, Cascina ^a   Tiberio, Oggionni ^a   Francesco, Bini ^a   Mario, Viganò ^a   Maria, Fietta Anna ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Azithromycin; Bronchiolitis obliterans syndrome; Clinical effect; Immunological effect; Lung transplant

Indexed keywords

8 ISOPROSTANE; AZATHIOPRINE; AZITHROMYCIN; CYCLOSPORIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG GRAFT REJECTION; LUNG LAVAGE; MALE; MORTALITY; NEUTROPHILIA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; CHEMOKINE CCL3; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INTERLEUKIN-8; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051682756     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01435.x     Document Type: Article

References (39)

1. Trulock EP, Christie JD, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007: 26: 782.
2. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002: 21: 297.
3. Lama VN, Murray S, Mumford JA et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005: 172: 379.
4. Hachem RR, Chakinala MM, Yusen RD et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004: 169: 468.
5. Nathan SD, Ross DJ, Belman MJ et al. Bronchiolitis obliterans in single-lung transplant recipients. Chest 1995: 107: 967.
6. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc 2006: 3: 444.
7. Belperio JA, Weigt SS, Fishbein MC, Lynch JP III. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009: 6: 108.
8. Meloni F, Vitulo P, Cascina A et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2004: 23: 1053.
9. Belperio JA, Keane MP, Burdick MD et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005: 115: 1150.
10. Neuringer IP, Chalermskulrat W, Aris R. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J Heart Lung Transplant 2005: 24: 3.
11. Snyder LD, Hartwig MG, Ganous T et al. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant. J Heart Lung Transplant 2006: 25: 1330.
12. Bharat A, Narayanan K, Street T et al. Early post transplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007: 83: 150.
13. Meloni F, Solari N, Miserere S et al. Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-beta, MIP3-alpha, MDC and their specific receptors. Transpl Immunol 2008: 18: 275.
14. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003: 168: 121.
15. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004: 77: 1465.
16. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005: 24: 1440.
17. Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005: 172: 772.
18. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006: 174: 566.
19. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008: 85: 36.
20. Fietta AM, Meloni F. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem 2008: 15: 716.
21. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 2008: 15: 199.
22. Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009: 87: 1538.
23. Vanaudenaerde BM, Meyts I, Vos R et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008: 32: 832.
24. Verleden GM, Dupont LJ, Vanhaecke J, Daenen W, Van Raemdonck DE. Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J Heart Lung Transplant 2005: 24: 1155.
25. Remund K, Rechsteiner T, Guo Z, Rentsch K, Boehler A. The macrolide clarithromycin inhibits experimental post-transplant bronchiolitis obliterans. Exp Lung Res 2009: 35: 830.
26. Meloni F, Morosini M, Solari N et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Human Immunol 2006: 67: 1.
27. Shen LS, Wang J, Shen DF et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009: 131: 109.
28. Jain R, Hachem RR, Morrell MR et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010: 29: 531.
29. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Van Raemdonck DE, Dupont LJ, Verleden GM. Plasma C-reactive protein levels correlate with markers of airway inflammation after lung transplantation: a role for systemic inflammation in bronchiolitis obliterans syndrome? Transpl Proc 2009: 41: 595.
30. Neuarohr C, Huppmann P, Samweber B et al., Munich Lung Transplant Group Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009: 28: 468.
31. Vanaudenaerde BM, Wuyts WA, Geudens N et al. Bronchoalveolar lavage fluid recovery correlates with airway neutrophilia in lung transplant patients. Respir Med 2007: 102: 339.
32. Verleden GM, Vos R, De Vleeschauwer SI et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009: 22: 771.
33. Remund KF, Best M, Egan JJ. Surgical therapies for lung disease: transplant and lung reduction. Proc Am Thorac Soc 2009: 6: 94.
34. Vos R, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Verleden GM. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant 2007: 7: 1278.
35. D'Ovidio F, Mura M, Tsang M et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005: 129: 1144.
36. Blondeau K, Mertens V, Vanaudenaerde BA et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2008: 31: 707.
37. Mertens V, Blondeau K, Pauwels A et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 2009: 54: 972.
38. Meloni F, Vitulo P, Bianco AM et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004: 77: 762.
39. Vos R, Vanaudenaerde BM, Verleden SE et al. A randomized placebo-controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2011: 37: 164.